Written answer
Cancer Services
401. Deputy Brendan Smith asked the Minister for Health in view of the success of the pilot lung cancer screening programme led by Beaumont RCSI Cancer Centre, if a national lung cancer screening programme will be rolled out at an early date. [80535/26]
Comment on this
I am committed to supporting Ireland's population screening programmes, which are a valuable part of our health service, enabling early treatment and care for many people and improving the overall health of our population.
The Programme for Government commits to evaluating the current lung cancer screening pilot in line with World Health Organization (WHO) criteria and developing recommendations on the way forward.
It should be emphasised that any proposed changes to Ireland's screening programmes will be considered through established, evidence-based processes. The National Screening Advisory Committee (NSAC) is an expert group that provides advice and recommendations to me on population-based screening. NSAC considers and assesses evidence against internationally accepted criteria before making recommendations.
The robust processes used by NSAC are essential to ensure screening programmes are effective, quality assured, and safe and that the benefits of screening outweigh potential harms. This is determined through Health Technology Assessments (HTAs), which are undertaken by the Health Information and Quality Authority (HIQA).
NSAC has received proposals through its annual Call for Submissions process seeking the introduction of a lung cancer screening programme. These proposals were considered in detail by the NSAC Cancer Screening Subgroup. On the basis of the available evidence, including emerging findings from the Beaumont Hospital/Royal College of Surgeons in Ireland (RCSI) Lung Health Check Pilot, the Subgroup recommended that lung cancer screening be referred to HIQA for a Health Technology Assessment.
The lung cancer screening HTA is expected to commence following completion of HIQA's ongoing HTA examining proposed expansions to the BreastCheck programme.
HTAs facilitate the assessment of relevant evidence and knowledge on the effects and consequences of healthcare technologies to guide decisions regarding the appropriate use of technology and efficient allocation of resources. They involve a multidisciplinary assessment of the clinical, economic, ethical, legal and societal perspectives that may be impacted by the introduction of a new technology. They are time-intensive and rigorous processes.
Finally, I would like to emphasise that population-based screening programmes are for people without symptoms. If anyone becomes aware of symptoms, or if they have concerns or worries, they should contact a medical professional immediately.